Abstract: A high-efficiency anti-tumor nano-drug delivery system containing hydralazine (hydralazine-nanoparticles abbreviated as H-NPs) is provided. The drug delivery system takes hydralazine and doxorubicin combined by a ?-? bond as a hydrophobic core and takes dextran as a hydrophilic shell. The high-effective anti-tumor nano-drug delivery system containing hydralazine can increase the vascular permeability and blood perfusion of the tumor site, improve the enrichment and penetration of nanoparticles in the tumor, reduce tumor hypoxia, increase the sensitivity of the tumor to a chemotherapy drug doxorubicin, and significantly improve its anti-tumor effect by expanding the tumor blood vessels and regulating tumor microenvironment (TME).
Type:
Grant
Filed:
March 2, 2023
Date of Patent:
October 17, 2023
Assignee:
SHANGHAI INSTITUTE FOR ADVANCED STUDY ZHE JIANG UNIVERSITY
Abstract: The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining low steady-state levels of, viral RNAs in host cells, and inducing and/or maintaining in viral latency. In one aspect, the invention provides vaccines that contain, or are produced from, viral nucleic acids in which the AGG sequences have been mutated. In another aspect, the invention provides methods and compositions for affecting the function of the AGG motif, and methods for identifying other INS sequences in viral genomes.
Type:
Grant
Filed:
August 4, 2016
Date of Patent:
October 27, 2020
Assignee:
INSTITUTE FOR ADVANCED STUDY
Inventors:
Raul Rabadan, Michael Krasnitz, Harlan Robins, Daniela Witten, Arnold Levine
Abstract: The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining low steady-state levels of, viral RNAs in host cells, and inducing and/or maintaining in viral latency. In one aspect, the invention provides vaccines that contain, or are produced from, viral nucleic acids in which the AGG sequences have been mutated. In another aspect, the invention provides methods and compositions for affecting the function of the AGG motif, and methods for identifying other INS sequences in viral genomes.
Type:
Application
Filed:
July 12, 2007
Publication date:
August 12, 2010
Applicant:
INSTITUTE FOR ADVANCED STUDY
Inventors:
Raul Rabadan, Michael Krasnitz, Harlan Robins, Daniela Witten, Arnold Levine